Surface
SmartShield Technology, a plasma coating applied to the lens; its layer composition and thickness are not published, on the product page or in the lens's FDA file.
Indication
Vision correction and therapeutic use, with therapeutic use requiring active oversight by the eye care practitioner.
Study
A one-year post-market study found severe corneal infection in 0.18% of wearers, 18 in 10,000 wearers, and a permanent reduction in vision of two or more rows of letters in 0.04%, 4 in 10,000.
Note
Approximately 80% of wearers tolerate extended wear, and about two-thirds achieve the full 30 nights of continuous wear.
